BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35703333)

  • 1. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
    Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
    Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis.
    Xu S; Huang H; Huang Y; Qian J; Wang X; Xu Z; Liu S; Liu J
    JAMA Surg; 2023 Jan; 158(1):73-79. PubMed ID: 36449303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
    Rosario PW; Mourão GF; Calsolari MR
    Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma.
    Gorshtein A; Benbassat C; Robenshtok E; Shimon I; Hirsch D
    World J Surg; 2016 Sep; 40(9):2123-30. PubMed ID: 27094559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
    Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
    Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma: All Risks, No Reward.
    Dismukes J; Fazendin J; Obiarinze R; Márquez GCH; Ramonell KM; Buczek E; Lindeman B; Chen H
    J Surg Res; 2021 Aug; 264():230-235. PubMed ID: 33838407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases.
    Matsuzu K; Sugino K; Masudo K; Nagahama M; Kitagawa W; Shibuya H; Ohkuwa K; Uruno T; Suzuki A; Magoshi S; Akaishi J; Masaki C; Kawano M; Suganuma N; Rino Y; Masuda M; Kameyama K; Takami H; Ito K
    World J Surg; 2014 Jan; 38(1):68-79. PubMed ID: 24081532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of multifocality in papillary thyroid carcinoma.
    Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
    J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two?
    Arora N; Turbendian HK; Kato MA; Moo TA; Zarnegar R; Fahey TJ
    Thyroid; 2009 May; 19(5):473-7. PubMed ID: 19348582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
    Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
    [No Abstract]   [Full Text] [Related]  

  • 15. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.
    Carr AA; Yen TWF; Ortiz DI; Hunt BC; Fareau G; Massey BL; Campbell BH; Doffek KL; Evans DB; Wang TS
    Thyroid; 2018 Nov; 28(11):1462-1467. PubMed ID: 30215297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
    Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
    Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center.
    Dobrinja C; Troian M; Cipolat Mis T; Rebez G; Bernardi S; Fabris B; Piscopello L; Makovac P; Di Gregorio F; de Manzini N
    Int J Surg; 2017 May; 41 Suppl 1():S40-S47. PubMed ID: 28506412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of risk factors of central lymph node metastasis and evaluation of the effect of prophylactic central neck dissection on migration of staging and risk stratification in patients with clinically node-negative papillary thyroid microcarcinoma.
    Yuan J; Li J; Chen X; Lin X; Du J; Zhao G; Chen Z; Wu Z
    Bull Cancer; 2017 Jun; 104(6):516-523. PubMed ID: 28476312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.